AUTHORS
Lihua Wu, Xiaofan Li Sr, MD, PhD2, Nainong Li, MD3
AFFILIATIONS
1 Fujian Medical University Union Hospital, Fuzhou, China
2 Fujian Medical University Union Hospital, Fuzhou, China
3 Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, China
ABSTRACT
Objective: Acute myeloid leukemia (AML) is a highly heterogeneous hematologic malignancy. Its progression is governed by both intrinsic genetic mutations in leukemic cells and abnormal remodeling of the bone marrow microenvironment (BMME). Leukemia-associated macrophages (LAMs) serve as central drivers of immunosuppression and inflammatory responses in AML, yet the core molecular mediators and signaling pathways responsible for their pro-leukemic functions remain poorly clarified. MAPKAPK2 (MK2), a key downstream kinase of the p38 MAPK cascade, mediates inflammatory stress responses; however, its function and detailed mechanism within the AML immune microenvironment have not been systematically investigated. This study integrated genetic causal inference, multi-omics bioinformatics analyses, cellular functional assays and mechanistic validation to elaborate how MK2 remodels IL-1β? LAMs and accelerates AML progression via the MK2/PTPN22–PI3K–AKT–mTOR signaling axis.
Methods: Mendelian randomization (MR) paired with sensitivity analyses using public genetic datasets confirmed the causal link between MK2 and AML onset and progression. Integrated TCGA-GTEx transcriptomic data were compared to assess MK2 expression differences between AML patients and healthy people, as well as its prognostic value. GEO single-cell RNA-seq data were processed routinely to map cell-specific MK2 distribution in marrow immune cells, focusing on MK2 enrichment in M2-like macrophages. Pathway enrichment and immune correlation analyses defined MK2-associated metabolic and immune pathways and built an MK2-centered immune regulatory network. We generated bone marrow-derived macrophage (BMDM) models with MK2 knockdown or overexpression. A C1498 AML cell-BMDM co-culture system and mouse AML models were used to test how MK2-altered macrophages regulate leukemic cell behaviors. CCK-8 and flow cytometry measured AML cell proliferation and apoptosis; flow cytometry also detected macrophage immunosuppressive polarization. Co-IP validated MK2-PTPN22 binding, and western blot assessed PI3K-AKT-mTOR phosphorylation and IL-1β levels. PTPN22 rescue assays under MK2 overexpression verified the essential role of this signaling cascade across molecular, cellular and functional levels.
Results: MR analyses confirmed MK2 causally promotes AML development (P < 0.05 for discovery and validation cohorts). MK2 was markedly overexpressed in AML tissues (P < 0.01), and high MK2 correlated with poor survival (HR = 1.85, 95% CI: 1.21–2.84, P < 0.01), supporting its utility as a prognostic biomarker. Single-cell results showed MK2 mainly localized to marrow macrophages, especially immunosuppressive M2 subsets, and positively correlated with monocyte (R = 0.350, P < 0.001) and M2 macrophage infiltration (R = 0.220, P < 0.01). MK2 upregulation polarized BMDMs toward a pro-tumor phenotype and induced IL-1β? LAM formation. In vitro co-culture and in vivo mouse experiments proved MK2-overexpressing macrophages boost C1498 proliferation and inhibit apoptosis. Mechanistically, MK2 directly binds PTPN22 without changing total PTPN22 protein abundance but suppresses its enzymatic activity, triggering sustained PI3K-AKT-mTOR activation and elevated IL-1β secretion. Restoring PTPN22 reversed pathway overactivation, lowered IL-1β, abolished macrophage pro-tumor features, and eliminated MK2-mediated AML progression. We summarized the complete cascade: MK2 binds and inactivates PTPN22, activates PI3K-AKT-mTOR signaling, remodels IL-1β? LAMs, and drives AML advancement.
Conclusions: Combining causal genetic analysis, multi-omics data, and in vitro/in vivo functional experiments, this study delineates the oncogenic role of MK2 in the AML bone marrow immune microenvironment. We uncovered a novel pathway: MK2 inhibits PTPN22 to maintain PI3K-AKT-mTOR activation, which reprograms pro-leukemic IL-1β? LAMs and accelerates AML progression. Our work offers novel mechanistic insights for microenvironment-targeted treatment and nominates MK2 as a potential therapeutic target for AML.
DISCLOSURES
Lihua Wu: No relevant conflicts of interest to declare.